876371-20-9 Usage
Chemical structure
1-Piperazinecarboxylic acid, 4-(trans-4-aminocyclohexyl)-, 1,1-dimethylethyl ester is a t-butyl ester of trans-4-(4-aminocyclohexyl)piperazinyl carboxylic acid.
Derivative
It is a derivative of piperazine.
Usage
Commonly used as a precursor in the pharmaceutical industry for various drugs, including antipsychotic and antihistamine medications.
Central nervous system effects
Studied for its potential effects on the central nervous system.
Drug delivery systems
Investigated for its potential use in drug delivery systems.
Building block
Used as a building block in the synthesis of various organic compounds.
Applications
Potential applications in drug development and medicinal chemistry.
Reactivity
Has a structure and reactivity that make it suitable for various applications in drug development and medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 876371-20-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,6,3,7 and 1 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 876371-20:
(8*8)+(7*7)+(6*6)+(5*3)+(4*7)+(3*1)+(2*2)+(1*0)=199
199 % 10 = 9
So 876371-20-9 is a valid CAS Registry Number.
876371-20-9Relevant academic research and scientific papers
ISOTHIAZOLO[5,4-D]PYRIMIDINE COMPOUND AS IRAK4 INHIBITOR
-
Paragraph 0127-0128; 0130, (2021/05/06)
Disclosed in the present invention are an IRAK4 inhibitor, and an application thereof in preparation of a drug for treating IRAK4-related diseases. Specifically disclosed are a compound represented by formula (III) and a pharmaceutically acceptable salt thereof.
IRAK DEGRADERS AND USES THEREOF
-
, (2020/06/19)
The present invention provides compounds, compositions thereof, and methods of using the same.
TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS
-
, (2020/10/19)
This invention is to methods for treating disorders involving abnormal cellular proliferation that have developed resistance to a selective CDK4/6 inhibitor.
IRAK DEGRADERS AND USES THEREOF
-
Paragraph 3739, (2019/07/10)
The present invention provides compounds, compositions thereof, and methods of using the same.
HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION
-
, (2019/07/20)
This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
